首页> Expert opinion on drug safety> Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

导出原文传递

翻译打印收藏纠错

第一作者： Hashimoto, Yoichiro

作者： Hashimoto, Yoichiro ^[1] ; Komori, Mika ^[2] ; Tanji, Yuka ^[3] ; Ozeki, Akichika ; Hirata, Koichi

作者单位： Eli Lilly,Eli Lilly Japan KK ^[1] Japan Drug Dev & Med Affairs,Eli Lilly Japan KK ^[2] Headache Ctr,Dokkyo Med Univ ^[3]

关键词 Cardiovascular risk factors headache Japan lasmiditan migraine disorders safety EPISODIC MIGRAINE PREVALENCE PROFILE PEOPLE

发布时间 2023-03-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Expert opinion on drug safety

2022年21卷7/12期

1495-1503页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Expert opinion on drug safety

2022年21卷7/12期

1495-1503页

检索历史清除

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Expert opinion on drug safety

相似文献

同项目论文

Expert opinion on drug safety

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Expert opinion on drug safety

相似文献

同项目论文

Expert opinion on drug safety

相关期刊

检索历史清除